Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of DTaP-Hep B-PRP-T vs Tritanrix-HepB/Hib in Filipino Infants
NCT00348881Phase 3Completed
- Sponsor
- Sanofi
- Start
- Jun 2006
- Primary completion
- Oct 2007
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of diphtheria + tetanus + acellular pertussis + hepatitis B + haemophilus influenzae type b conjugate vaccine in diphtheria, Tetanus, pertussis and 2 more (2 arms), sponsored by Sanofi. Primary endpoints: Number of Participants With Seroprotection for Anti-Hep Bs, Anti-PRP, Anti-Tetanus, and Anti-Diphtheria Antibodies and Number of Participants With Observed High Fever. Started Jun 2006; status: completed.
02
Drugs
diphtheria + tetanus + acellular pertussis + hepatitis B + haemophilus influenzae type b conjugate vaccine
03
Conditions
diphtheriaTetanuspertussishepatitis B (HBV)Haemophilus influenzae type b infection (Hib)
Beyond the preview
Go deeper on NCT00348881.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00348881.